Drugs / IBI-10090
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01214174 | Oct 2010 → May 2012 | — | ICON Bioscience Inc | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02006888 | Jan → Oct 2014 | cataract | ICON Bioscience Inc | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI-10090 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01214174 ↗ |